Using orthotopic cancer mouse models, it was shown that PRL3-zumab reduces tumor growth, inhibits metastatic tumors, reduces tumor recurrence, and increases survival 8, 150, 151, 153. Here, PTP4A3 is linked to metastatic neoplasm.